Thursday, May 28, 2015 7:16:34 AM
Brando5 you do realize the analyst price was higher than that a year ago?? I am just curious how long you have been in this stock? I do believe in there science I have been posting and promoting NBS for years(on this board about 6 months).
You do realize that they did a reverse split to get listed, when they did that the shares where worth 50cents a share BEFORE we had NBS20! They did a 10-1 split in June of 2013 so shares went up to $5 a share if you had 1000 shares at 50cents you now owned 100 shares at $5 again BEFORE we had NBS20! Now after all there achievement's which there has been a lot! I have posted them continuously and now we have NBS20 the shares will probably open at $2 a share!!(right now as I post it is $2.12 premarket) Those who where invested back in 2013 at 50 cents a share now have a equivalent of 20 cents a share after all of there time invested! That includes the good news from NBS10 and the purchase of NBS20 and we have lost more than half our value!
I have been invested in Bios for a very long time, I have made a lot of money also. This companies science I believe in with out a doubt! BUT YES I AM PISSED!! It is hard to believe they did not announce this Dollar for Dollar a head of this! How do they expect to keep investors when they build them up then kick them in the ass?? You talk about the analyst target price it use to be around $28 a share a year ago, they have not come near that. Yes maybe 3-5 yrs down the road they might.
You said "" The underwriter bought for $2 a share doesn't mean you can get it for that price now!"" you will be able to sometime today! You also said "" They bought $25 million dollars worth! You won't get $2 a share buying $500 worth!"" I think you will be rethinking that statement by noon! You also said "" Keep in mind this company has target prices from $12-$24 a share."" They had even a higher target price before NBS20!
I am very troubled why this company continues to go down on really good news!
THIS SEEMS TO ME TO HAVE ONLY BENIFITTED PEOPLE SHORTING THE COMPANY! hOW ABOUT THE LONGS???
You do realize that they did a reverse split to get listed, when they did that the shares where worth 50cents a share BEFORE we had NBS20! They did a 10-1 split in June of 2013 so shares went up to $5 a share if you had 1000 shares at 50cents you now owned 100 shares at $5 again BEFORE we had NBS20! Now after all there achievement's which there has been a lot! I have posted them continuously and now we have NBS20 the shares will probably open at $2 a share!!(right now as I post it is $2.12 premarket) Those who where invested back in 2013 at 50 cents a share now have a equivalent of 20 cents a share after all of there time invested! That includes the good news from NBS10 and the purchase of NBS20 and we have lost more than half our value!
I have been invested in Bios for a very long time, I have made a lot of money also. This companies science I believe in with out a doubt! BUT YES I AM PISSED!! It is hard to believe they did not announce this Dollar for Dollar a head of this! How do they expect to keep investors when they build them up then kick them in the ass?? You talk about the analyst target price it use to be around $28 a share a year ago, they have not come near that. Yes maybe 3-5 yrs down the road they might.
You said "" The underwriter bought for $2 a share doesn't mean you can get it for that price now!"" you will be able to sometime today! You also said "" They bought $25 million dollars worth! You won't get $2 a share buying $500 worth!"" I think you will be rethinking that statement by noon! You also said "" Keep in mind this company has target prices from $12-$24 a share."" They had even a higher target price before NBS20!
I am very troubled why this company continues to go down on really good news!
THIS SEEMS TO ME TO HAVE ONLY BENIFITTED PEOPLE SHORTING THE COMPANY! hOW ABOUT THE LONGS???
Recent LSTA News
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. • GlobeNewswire Inc. • 03/06/2026 11:15:05 PM
- Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide • GlobeNewswire Inc. • 01/27/2026 01:00:00 PM
- All-Cash Buyout Sparks Breakout Move in Biotech Name • AllPennyStocks.com • 01/21/2026 04:14:37 PM
- Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium • IH Market News • 01/21/2026 03:41:11 PM
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer • GlobeNewswire Inc. • 01/21/2026 12:00:00 PM
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/06/2025 09:05:00 PM
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ • GlobeNewswire Inc. • 11/06/2025 01:00:00 PM
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent • GlobeNewswire Inc. • 11/04/2025 09:00:00 PM
- Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 • GlobeNewswire Inc. • 10/30/2025 12:00:00 PM
- Lisata Therapeutics to Present at LD Micro Main Event XIX • Newsfile • 10/13/2025 12:00:00 PM
- Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement • GlobeNewswire Inc. • 10/08/2025 12:30:00 PM
- Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial • GlobeNewswire Inc. • 09/29/2025 12:00:00 PM
- Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/02/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 08:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 08:09:29 PM
- Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/07/2025 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 • GlobeNewswire Inc. • 07/31/2025 12:00:00 PM
- Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update • GlobeNewswire Inc. • 07/17/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2025 12:00:44 PM
- Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide • GlobeNewswire Inc. • 07/15/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 12:38:40 PM
- Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 06/26/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2025 01:13:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 08:02:11 PM
- Lisata Therapeutics to Present at the 2025 BIO International Convention • GlobeNewswire Inc. • 06/11/2025 12:30:00 PM
